What does Augme® Technologies do?

Augme® Technologies, Inc. (OTC.BB: AUGT) provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Selling its products and services under the Hipcricket brand, Augme's platform has provided measurable successes across an industry-leading 200,000+ campaigns for its clients, which include many of America's brand-name leaders (e.g., Macy's, MillerCoors, Nestle, Clear Channel) in a variety of industries, along with their agencies. Augme's offerings allow marketers, brands, and agencies to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, MMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Augme's AD LIFE® platform facilitates consumer brand interaction and the ability to track and analyze campaign results. Using its own patented device-detection and proprietary mobile content adaptation software, AD LIFE solves the mobile marketing industry problem of disparate operating systems, device types, and on-screen mobile content rendering. Augme also provides business-to-consumer solutions, including national mobile couponing campaigns, strategic mobile healthcare tools, custom mobile application development, and consumer data tracking and analytics. In addition to AD LIFE, Augme in 2011 acquired the assets of Hipcricket, Inc. and JAGTAG, Inc. and licenses the digital broadcast platform BOOMBOX®. Augme is headquartered in New York City, with operations in Seattle, Atlanta, Dallas, Los Angeles, San Francisco, Chicago, Miami and Tucson.

Augme Technologies™, Augme®, Hipcricket®, AD LIFE®, BOOMBOX®, AD SERVE® and the Augme logo are trademarks of Augme Technologies, Inc. All rights reserved. 2009-12.

What does Hipcricket do?

Hipcricket, a wholly owned subsidiary of Augme Technologies, Inc. (OTC.BB: AUGT), is the one-stop mobile marketing and advertising company that empowers brands, agencies and media properties to engage customers, drive loyalty and increase sales. Hipcricket's customers connect with consumers across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Hipcricket's proven technology, strategic and marketing services and experienced account management teams have provided measurable success to a broad range of national and regional brand-name leaders (e.g., Macy's, MillerCoors, Nestle, Clear Channel) across and industry-leading 200,000+ campaigns. The company has also created the first comprehensive mobile ad network that taps into the buying power of the mass market with industry-leading capabilities to target customers via location and highly-specific demographic information across SMS, display, rich media and video. Hipcricket is headquartered in New York, with operations in Seattle, Dallas, Chicago, Atlanta, Los Angeles, San Francisco, and Miami. To find out more about Hipcricket, please contact us at www.hipcricket.com.  

What stock exhange does Augme® Technologies trade on and what is its ticker symbol?

Augme® Technologies' shares are traded on the Over the Counter Bulletin Board (OTCBB) under the ticker symbol AUGT.

Where are Augme® Technologies' headquarters located?

Augme® Technologies’ headquarters are located at 350 7^th Avenue, 2nd Floor, New York, NY 10001. Our telephone number is (855) 423-5433.

Who should I contact regarding my Augme Technologies™ stock certificate?

Manhattan Transfer Registrar Company is Augme Technologies'™ transfer agent and administers all matters related to stock that is directly registered with Augme Technologies.
Contact:
Manhattan Transfer Registrar Company
57 Eastwood Road
Miller Place, NY 11764
www.mtrco.com
800.786.0362 Office
631.201.8143 Fax

If your stock is held by a brokerage firm, please contact your broker directly.

Who is the Transfer Agent for Augme Technologies™?

Manhattan Transfer Registrar Company is Augme Technologies'™ transfer agent and administers all matters related to stock that is directly registered with Augme Technologies.
Contact:
Manhattan Transfer Registrar Company
57 Eastwood Road
Miller Place, NY 11764
www.mtrco.com
800.786.0362 Office
631.201.8143 Fax

If your stock is held by a brokerage firm, please contact your broker directly.

When does Augme® Technologies’ fiscal year end?

Augme® Technologies’ fiscal year ends February 29, 2012.

How do I request financial materials?

Please refer to the Financial Reporting tab on our website where you can download the appropriate materials.

Does Augme® Technologies pay dividends?

Augme® Technologies does not intend to declare or pay cash dividends on its capital stock in the foreseeable future.

Does Augme® Technologies have a direct purchase plan for its common stock?

Augme® Technologies does not currently offer a direct stock purchase plan. Our stock can be purchased or sold through a financial institution such as a brokerage firm. Augme® Technologies is working on establishing such a plan.

Who are Augme® Technologies’ independent accountants?

Augme® Technologies’ independent accountants are Moss Adams LLP.

How can I get a copy of Augme® Technologies’ prospectus?

A copy of the final prospectus relating to this offering may be obtained from Augme® Technologies’ Headquarters located in New York at 350 7th Avenue, 2nd Floor, New York, NY 10001. Our telephone number is (855) 423-5433. Alternatively you can visit www.sec.gov.

When was Augme® Technologies incorporated?

Founded in 1999 the Company provided strategic services and mobile technology to leading consumers and healthcare brands. The Company, formerly known as Modavox, Inc., changed its name to Augme® Technologies, Inc. in February 2010. Augme® is a Delaware Corporation.

Who were the underwriters for Augme® Technologies’ recent secondary offering?

Augme® Technologies completed a $20.2M Public Offering. Northland Capital Markets acted as the lead bookrunner, and ThinkEquity LLC and Brean Murray, Carret & Co. acted as co-managers in the offering.

How many common shares of stock are authorized by Augme® Technologies?

250 million.

How many common shares of Augme® Technologies stock are outstanding?

Approximately 98.6 million as of June 15, 2012.

How many preferred shares of stock are authorized Augme® Technologies?

25 million.

How many preferred shares of Augme® Technologies stock are outstanding?

None.

Does Augme® Technologies have any long-term or short-term debt?

No.

How many Augme® Technologies’ options and warrants are outstanding?

Approximately 28 million.

What is the average exercise price of Augme® Technologies’ options and warrants?

Approximately $2.02 per share.